NCT06414460View on ClinicalTrials.gov

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Locally Advanced/Metastatic Solid Tumors
Interventions
DRUG

ISM3412

ISM3412 will be administered orally once daily.

Trial Locations (5)

37203

RECRUITING

SCRI Oncology Partners, Nashville

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

Unknown

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

RECRUITING

Shanghai Gobroad Cancer Hospital, Shanghai

All Listed Sponsors
lead

InSilico Medicine Hong Kong Limited

INDUSTRY